Clinical Trial Search

Primary: Number of Dose Limiting Toxicities — 0; 2 DLTs

Primary: Number of Patients With Abdominal Recurrence or Death — 72; 73; 61; 60 Participants — p=0.955

Primary: Pathologic Response Rate, Defined as the Percentage of Participants With Greater Than or Equal to 95% Necrosis. — 20 % of participants

Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years

Primary: Number of Participants With Overall Response (OR) — 1 participants

Primary: Local Disease Control Assessed by Physical Examination — 0 Participants

Primary: Late Radiation Toxicities at 2 Years From the Start of Radiation Treatment — 0 Participants

Primary: Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme. — 145…

Primary: Cumulative Incidence Rate of Local Recurrence and Competing Risks (All Patients) — 16.89; 10.42 percentage of participants

Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events

Primary: Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)

Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants

Primary: Clinical Benefit Rate — 22 Participants

Primary: Tumor Best Response Rate — 0 Participants

Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months

Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient

Primary: Overall Objective Response — 5; 22; 8 participants

Primary: Best Anatomical Tumor Response — 0; 2; 22; 30 participants

Primary: Rate of Late Radiation Morbidity (≥ Grade 2 Lymphedema, Subcutaneous Fibrosis, or Joint Stiffness) at 2 Years From the Start of Radiotherapy as Measured by EORTC/RTOG…

Primary: Change in Maximum SUV of Tumors Measured by FDG-PET Pre- and Post Receipt of Pazopanib Versus Placebo — -0.1; -0.1 Standardized uptake value-SUV — p=0.4

Primary: Response Rate (CR + PR) Assessed by RECIST 1.1 (Phase II) — 4; 1; 5; 0 participants

Primary: Percentage of Patients With Progression-free Survival at 16 Weeks. — 36.4 Percentage of patients

Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants

Primary: Rate of Complete Tumor Necrosis — 4 Participants

Primary: Best Overall Response Rates by Week 16 (ITT) — 0; 0; 0; 0 percentage of participants — p=0.1

Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants

Primary: Response Rate for Amrubicin in Patients With Metastatic or Advanced Sarcoma as First Line Therapy. — 13 percentage of pt with a partial response

Primary: Progression-free Survival — 1.8; 3.7 months

Primary: Disease Control Rate, Defined as the Number of Patients Who Achieved Complete Response, Partial Response or Stable Disease For a Period of More Than 4 Months. — 0…

Primary: Progression Free Survival at Week 12 — 0; 0; 0; 0 participants — p=0.653